Elster A D
Department of Radiology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27103.
Radiology. 1990 Jul;176(1):225-30. doi: 10.1148/radiology.176.1.2353096.
Gadopentetate dimeglumine (gadolinium diethylenetriaminepentaacetic acid [DTPA]) was prospectively administered to 15 consecutive neonates and young infants (less than 6 weeks old) referred for routine cranial magnetic resonance (MR) imaging. The goals of the study were (a) to provide preliminary safety and efficacy data concerning the use of this drug in neonates and (b) to determine whether the patterns and time course of normal contrast material enhancement were similar to those seen in older children and adults. Gd-DTPA-enhanced MR images revealed significant abnormalities not seen on the MR images obtained before administration of contrast material in four (27%) of 15 patients. The adult dose (0.1 mmol/kg) provided bright enhancement of normal intracranial structures. Because of significantly reduced glomerular filtration and renal clearance rates in newborns, vivid contrast enhancement of normal structures was seen to persist for several hours after injection. A prolonged window of time for imaging may therefore exist for neonates and young infants.
钆喷酸葡胺（钆二乙烯三胺五乙酸[DTPA]）被前瞻性地给予15例连续转诊进行常规头颅磁共振（MR）成像的新生儿和小婴儿（小于6周龄）。该研究的目的是：（a）提供有关该药物在新生儿中使用的初步安全性和有效性数据；（b）确定正常对比剂增强的模式和时间过程是否与较大儿童和成人中所见的相似。钆喷酸葡胺增强的MR图像显示，15例患者中有4例（27%）在注射对比剂前获得的MR图像上未发现的明显异常。成人剂量（0.1 mmol/kg）使正常颅内结构得到明显增强。由于新生儿的肾小球滤过率和肾清除率显著降低，正常结构的鲜明对比增强在注射后可持续数小时。因此，新生儿和小婴儿可能存在延长的成像时间窗。
